摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,4-dimethyl-cycloheptanecarboxylic acid amide | 99175-64-1

中文名称
——
中文别名
——
英文名称
4,4-dimethyl-cycloheptanecarboxylic acid amide
英文别名
4,4-Dimethyl-cycloheptancarbonsaeure-amid;4,4-Dimethylcycloheptane-1-carboxamide
4,4-dimethyl-cycloheptanecarboxylic acid amide化学式
CAS
99175-64-1
化学式
C10H19NO
mdl
——
分子量
169.267
InChiKey
JRMNZRVJIVTWGN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    43.1
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 生成 4,4-dimethyl-cycloheptanecarboxylic acid amide
    参考文献:
    名称:
    对来自 LIBOCEDRUS FORMOSANA, FLORIN 木材的两种特征挥发性酸之一的 Shonanic 酸组成的研究。一、湘南酸的分离及其一般性质
    摘要:
    (1) 据报道,在台湾 Libocedrus、Florin 或“湘南木”的木材的挥发性部分中存在一种未知的酸。(2) Shonanic acid 是一种不饱和的一元酸,具有分子式为 C10H14O2 的单环结构,熔点 40-41°。它的酰胺在 116-117° 熔化,苯胺在 111-112° 熔化。(3) 湘南酸在催化还原时吸收四个氢原子可以转化为四氢湘酸,而它只吸收两个原子的溴,当用钠和乙醇还原时形成不饱和酸,即。得到二氢脂肪酸 (C10H16O2)。这些实验事实,再加上湘南酸的分子折射表现出显着的提升,得出的结论是其分子中存在共轭双键。(4) 虽然四氢芴酰胺在144°熔化,但证明该酸与二氢-α-樟脑酸(C10H18O2,酰胺熔点144°)有很大不同。(5)湘南酸异构化为异湘酸b...
    DOI:
    10.1246/bcsj.11.759
点击查看最新优质反应信息

文献信息

  • GLP-1 receptor modulators
    申请人:Celgene International II SÀRL
    公开号:US10034886B2
    公开(公告)日:2018-07-31
    Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
    本研究提供了调节胰高血糖素样肽 1(GLP-1)受体的化合物及其合成方法,以及治疗和/或预防使用方法。此类化合物可单独作为 GLP-1 受体的调节剂或增效剂,或与 GLP-1(7-36) 和 GLP-1(9-36)等增量肽一起使用,或与艾塞那肽利拉鲁肽等肽类疗法一起使用,并具有以下一般结构(其中""代表化合物的 R 和 S 形式中的一种或两种): 其中 A、B、C、Y1、Y2、Z、R1、R2、R3、R4、R5、W1、n、p 和 q 如本文所定义。
  • Multiple attention systems in perceptual categorization
    作者:W. Todd Maddox、F. Gregory Ashby、Elliott M. Waldron
    DOI:10.3758/bf03194934
    日期:2002.4
    Five observers categorized inverted L-shaped stimuli according to the length of the horizontal line segment. A centrally located spatial cue preceded the stimulus on each trial. On 80% of the trials, the (relevant) horizontal line segment fell within the cued location, and on 20% of the trials the (irrelevant) vertical line segment fell within the cued location. The empirical results provide support for the hypothesis that perceptual attention can focus on the stimulus attribute inside the spatially cued location at the same time that decisional attention is focused on the (relevant) horizontal attribute-that is, the results suggest that perceptual and decisional attention can function independently during categorization. Decision bound models and extended generalized context models that assume separate perceptual and decisional attention systems were fitted to the data. Versions of the models that assume that the spatial cue affected perceptual attention were superior to versions that assume no effect on perceptual attention. These theoretical analyses support the functional independence hypothesis and suggest that formal theories of categorization should model the effects of perceptual and decisional attention separately.
  • NOVEL GLP-1 RECEPTOR MODULATORS
    申请人:Celgene International II SÀRL
    公开号:US20180021346A1
    公开(公告)日:2018-01-25
    Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ ” represents either or both the R and S form of the compound): where A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸